Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

With -w, grep will match “error” but skip things like “errors” or “terror.” The difference can be subtle, but when you’re trying to be precise, it matters a lot. I use this when I’m searching through ...

Toward the end of this decade, a choice may face the species that could reshape its interactions with intelligence itself and this choice is whether or not it shall allow highly advanced AI systems to ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

AI isn’t neutral in women’s health. It involves learning from visibility gaps shaped by brand safety, search authority, and ...

Across five funds, ARK averaged a 39.54% return, underscoring a sharp rebound for Wood’s high-conviction bets in robotics, ...